New CFO for InDex Pharmaceuticals Holding

InDex Pharmaceuticals Holding AB, a pharmaceutical development company focusing on immunological diseases, has appointed Johan Giléus as new Chief Financial Officer (CFO) who will take over his new duties from May 1, 2017.

InDex Pharmaceuticals’ current CFO, Per-Olof Gunnesson who has been the CFO since 2003, will remain engaged with the company as a consultant, focusing primarily on contractual issues.

Giléus is an independent financial advisor, having spent 25 years with Deloitte, where he – among other things – as partner headed up the Transaction Services function with some 30 professionals and served on the board of Deloitte Sweden.

He has extensive experience of accounting and financial reporting in publicly traded companies and other issues regarding the stock market, risk management and strategic transactions. Giléus participated as a consultant in the work with InDex Pharmaceuticals’ IPO during 2016 and has since then advised the company on financial reporting matters as a listed company.

“I am looking forward to work with Johan and welcome him to the InDex management team at this exciting time for the company,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. “As a newly listed company it feels very reassuring with Johan’s expertise and extensive experience of the public environment.”